2026 and 2027 Financial Updates. Moderna is expanding its cost efficiency and prioritization programs and expects estimated GAAP operating costs of $5.4 to $5.7 billion in 2026, a reduction from ...

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...

CAMBRIDGE, MA / ACCESS Newswire / May 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2025. "In the first quarter, we ...